Global Cancer Immunotherapies Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
As the global economy mends, the 2021 growth of Cancer Immunotherapies will have significant change from previous year. According to our (LP Information) latest study, the global Cancer Immunotherapies market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Cancer Immunotherapies market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Cancer Immunotherapies market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Cancer Immunotherapies market, reaching US$ million by the year 2028. As for the Europe Cancer Immunotherapies landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Cancer Immunotherapies players cover Amgen, AstraZeneca, Roche, and Bristol-Myers Squibb, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
As the global economy mends, the 2021 growth of Cancer Immunotherapies will have significant change from previous year. According to our (LP Information) latest study, the global Cancer Immunotherapies market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Cancer Immunotherapies market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Cancer Immunotherapies market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Cancer Immunotherapies market, reaching US$ million by the year 2028. As for the Europe Cancer Immunotherapies landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Cancer Immunotherapies players cover Amgen, AstraZeneca, Roche, and Bristol-Myers Squibb, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
- Monoclonal Antibodies (MABs)
- Cancer Vaccines
- Immunomodulators
- Adoptive Cell transfer
- Checkpoint Inhibitors
- Breast Cancer
- Leukemia
- Lymphoma
- Melanoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- AstraZeneca
- Roche
- Bristol-Myers Squibb
- Bayer
- Merck
- ARMO BioSciences (Eli Lilly)
- Novartis
- Pfizer
- Johnson & Johnson
- AbbVie
- Gilead Sciences
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cancer Immunotherapies Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Cancer Immunotherapies by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Cancer Immunotherapies by Country/Region, 2017, 2022 & 2028
2.2 Cancer Immunotherapies Segment by Type
2.2.1 Monoclonal Antibodies (MABs)
2.2.2 Cancer Vaccines
2.2.3 Immunomodulators
2.2.4 Adoptive Cell transfer
2.2.5 Checkpoint Inhibitors
2.3 Cancer Immunotherapies Sales by Type
2.3.1 Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
2.3.2 Global Cancer Immunotherapies Revenue and Market Share by Type (2017-2022)
2.3.3 Global Cancer Immunotherapies Sale Price by Type (2017-2022)
2.4 Cancer Immunotherapies Segment by Application
2.4.1 Breast Cancer
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Melanoma
2.4.5 Colorectal Cancer
2.4.6 Non-Small Cell Lung Cancer
2.5 Cancer Immunotherapies Sales by Application
2.5.1 Global Cancer Immunotherapies Sale Market Share by Application (2017-2022)
2.5.2 Global Cancer Immunotherapies Revenue and Market Share by Application (2017-2022)
2.5.3 Global Cancer Immunotherapies Sale Price by Application (2017-2022)
3 GLOBAL CANCER IMMUNOTHERAPIES BY COMPANY
3.1 Global Cancer Immunotherapies Breakdown Data by Company
3.1.1 Global Cancer Immunotherapies Annual Sales by Company (2020-2022)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Company (2020-2022)
3.2 Global Cancer Immunotherapies Annual Revenue by Company (2020-2022)
3.2.1 Global Cancer Immunotherapies Revenue by Company (2020-2022)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Company (2020-2022)
3.3 Global Cancer Immunotherapies Sale Price by Company
3.4 Key Manufacturers Cancer Immunotherapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Immunotherapies Product Location Distribution
3.4.2 Players Cancer Immunotherapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Cancer Immunotherapies Market Size by Geographic Region (2017-2022)
4.1.1 Global Cancer Immunotherapies Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Cancer Immunotherapies Annual Revenue by Geographic Region
4.2 World Historic Cancer Immunotherapies Market Size by Country/Region (2017-2022)
4.2.1 Global Cancer Immunotherapies Annual Sales by Country/Region (2017-2022)
4.2.2 Global Cancer Immunotherapies Annual Revenue by Country/Region
4.3 Americas Cancer Immunotherapies Sales Growth
4.4 APAC Cancer Immunotherapies Sales Growth
4.5 Europe Cancer Immunotherapies Sales Growth
4.6 Middle East & Africa Cancer Immunotherapies Sales Growth
5 AMERICAS
5.1 Americas Cancer Immunotherapies Sales by Country
5.1.1 Americas Cancer Immunotherapies Sales by Country (2017-2022)
5.1.2 Americas Cancer Immunotherapies Revenue by Country (2017-2022)
5.2 Americas Cancer Immunotherapies Sales by Type
5.3 Americas Cancer Immunotherapies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapies Sales by Region
6.1.1 APAC Cancer Immunotherapies Sales by Region (2017-2022)
6.1.2 APAC Cancer Immunotherapies Revenue by Region (2017-2022)
6.2 APAC Cancer Immunotherapies Sales by Type
6.3 APAC Cancer Immunotherapies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country (2017-2022)
7.1.2 Europe Cancer Immunotherapies Revenue by Country (2017-2022)
7.2 Europe Cancer Immunotherapies Sales by Type
7.3 Europe Cancer Immunotherapies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cancer Immunotherapies by Country
8.1.1 Middle East & Africa Cancer Immunotherapies Sales by Country (2017-2022)
8.1.2 Middle East & Africa Cancer Immunotherapies Revenue by Country (2017-2022)
8.2 Middle East & Africa Cancer Immunotherapies Sales by Type
8.3 Middle East & Africa Cancer Immunotherapies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapies
10.3 Manufacturing Process Analysis of Cancer Immunotherapies
10.4 Industry Chain Structure of Cancer Immunotherapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Immunotherapies Distributors
11.3 Cancer Immunotherapies Customer
12 WORLD FORECAST REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
12.1 Global Cancer Immunotherapies Market Size Forecast by Region
12.1.1 Global Cancer Immunotherapies Forecast by Region (2023-2028)
12.1.2 Global Cancer Immunotherapies Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cancer Immunotherapies Forecast by Type
12.7 Global Cancer Immunotherapies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Cancer Immunotherapies Product Offered
13.1.3 Amgen Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Cancer Immunotherapies Product Offered
13.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Cancer Immunotherapies Product Offered
13.3.3 Roche Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Cancer Immunotherapies Product Offered
13.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Cancer Immunotherapies Product Offered
13.5.3 Bayer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Cancer Immunotherapies Product Offered
13.6.3 Merck Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 ARMO BioSciences (Eli Lilly)
13.7.1 ARMO BioSciences (Eli Lilly) Company Information
13.7.2 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Offered
13.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 ARMO BioSciences (Eli Lilly) Main Business Overview
13.7.5 ARMO BioSciences (Eli Lilly) Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Cancer Immunotherapies Product Offered
13.8.3 Novartis Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Cancer Immunotherapies Product Offered
13.9.3 Pfizer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson Cancer Immunotherapies Product Offered
13.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Cancer Immunotherapies Product Offered
13.11.3 AbbVie Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Gilead Sciences
13.12.1 Gilead Sciences Company Information
13.12.2 Gilead Sciences Cancer Immunotherapies Product Offered
13.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Gilead Sciences Main Business Overview
13.12.5 Gilead Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cancer Immunotherapies Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Cancer Immunotherapies by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Cancer Immunotherapies by Country/Region, 2017, 2022 & 2028
2.2 Cancer Immunotherapies Segment by Type
2.2.1 Monoclonal Antibodies (MABs)
2.2.2 Cancer Vaccines
2.2.3 Immunomodulators
2.2.4 Adoptive Cell transfer
2.2.5 Checkpoint Inhibitors
2.3 Cancer Immunotherapies Sales by Type
2.3.1 Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
2.3.2 Global Cancer Immunotherapies Revenue and Market Share by Type (2017-2022)
2.3.3 Global Cancer Immunotherapies Sale Price by Type (2017-2022)
2.4 Cancer Immunotherapies Segment by Application
2.4.1 Breast Cancer
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Melanoma
2.4.5 Colorectal Cancer
2.4.6 Non-Small Cell Lung Cancer
2.5 Cancer Immunotherapies Sales by Application
2.5.1 Global Cancer Immunotherapies Sale Market Share by Application (2017-2022)
2.5.2 Global Cancer Immunotherapies Revenue and Market Share by Application (2017-2022)
2.5.3 Global Cancer Immunotherapies Sale Price by Application (2017-2022)
3 GLOBAL CANCER IMMUNOTHERAPIES BY COMPANY
3.1 Global Cancer Immunotherapies Breakdown Data by Company
3.1.1 Global Cancer Immunotherapies Annual Sales by Company (2020-2022)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Company (2020-2022)
3.2 Global Cancer Immunotherapies Annual Revenue by Company (2020-2022)
3.2.1 Global Cancer Immunotherapies Revenue by Company (2020-2022)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Company (2020-2022)
3.3 Global Cancer Immunotherapies Sale Price by Company
3.4 Key Manufacturers Cancer Immunotherapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Immunotherapies Product Location Distribution
3.4.2 Players Cancer Immunotherapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Cancer Immunotherapies Market Size by Geographic Region (2017-2022)
4.1.1 Global Cancer Immunotherapies Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Cancer Immunotherapies Annual Revenue by Geographic Region
4.2 World Historic Cancer Immunotherapies Market Size by Country/Region (2017-2022)
4.2.1 Global Cancer Immunotherapies Annual Sales by Country/Region (2017-2022)
4.2.2 Global Cancer Immunotherapies Annual Revenue by Country/Region
4.3 Americas Cancer Immunotherapies Sales Growth
4.4 APAC Cancer Immunotherapies Sales Growth
4.5 Europe Cancer Immunotherapies Sales Growth
4.6 Middle East & Africa Cancer Immunotherapies Sales Growth
5 AMERICAS
5.1 Americas Cancer Immunotherapies Sales by Country
5.1.1 Americas Cancer Immunotherapies Sales by Country (2017-2022)
5.1.2 Americas Cancer Immunotherapies Revenue by Country (2017-2022)
5.2 Americas Cancer Immunotherapies Sales by Type
5.3 Americas Cancer Immunotherapies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapies Sales by Region
6.1.1 APAC Cancer Immunotherapies Sales by Region (2017-2022)
6.1.2 APAC Cancer Immunotherapies Revenue by Region (2017-2022)
6.2 APAC Cancer Immunotherapies Sales by Type
6.3 APAC Cancer Immunotherapies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country (2017-2022)
7.1.2 Europe Cancer Immunotherapies Revenue by Country (2017-2022)
7.2 Europe Cancer Immunotherapies Sales by Type
7.3 Europe Cancer Immunotherapies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cancer Immunotherapies by Country
8.1.1 Middle East & Africa Cancer Immunotherapies Sales by Country (2017-2022)
8.1.2 Middle East & Africa Cancer Immunotherapies Revenue by Country (2017-2022)
8.2 Middle East & Africa Cancer Immunotherapies Sales by Type
8.3 Middle East & Africa Cancer Immunotherapies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapies
10.3 Manufacturing Process Analysis of Cancer Immunotherapies
10.4 Industry Chain Structure of Cancer Immunotherapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Immunotherapies Distributors
11.3 Cancer Immunotherapies Customer
12 WORLD FORECAST REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
12.1 Global Cancer Immunotherapies Market Size Forecast by Region
12.1.1 Global Cancer Immunotherapies Forecast by Region (2023-2028)
12.1.2 Global Cancer Immunotherapies Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cancer Immunotherapies Forecast by Type
12.7 Global Cancer Immunotherapies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Cancer Immunotherapies Product Offered
13.1.3 Amgen Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Cancer Immunotherapies Product Offered
13.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Cancer Immunotherapies Product Offered
13.3.3 Roche Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Cancer Immunotherapies Product Offered
13.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Cancer Immunotherapies Product Offered
13.5.3 Bayer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Cancer Immunotherapies Product Offered
13.6.3 Merck Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 ARMO BioSciences (Eli Lilly)
13.7.1 ARMO BioSciences (Eli Lilly) Company Information
13.7.2 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Offered
13.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 ARMO BioSciences (Eli Lilly) Main Business Overview
13.7.5 ARMO BioSciences (Eli Lilly) Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Cancer Immunotherapies Product Offered
13.8.3 Novartis Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Cancer Immunotherapies Product Offered
13.9.3 Pfizer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson Cancer Immunotherapies Product Offered
13.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Cancer Immunotherapies Product Offered
13.11.3 AbbVie Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Gilead Sciences
13.12.1 Gilead Sciences Company Information
13.12.2 Gilead Sciences Cancer Immunotherapies Product Offered
13.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Gilead Sciences Main Business Overview
13.12.5 Gilead Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Cancer Immunotherapies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Cancer Immunotherapies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies (MABs)
Table 4. Major Players of Cancer Vaccines
Table 5. Major Players of Immunomodulators
Table 6. Major Players of Adoptive Cell transfer
Table 7. Major Players of Checkpoint Inhibitors
Table 8. Global Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 9. Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 10. Global Cancer Immunotherapies Revenue by Type (2017-2022) & ($ million)
Table 11. Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
Table 12. Global Cancer Immunotherapies Sale Price by Type (2017-2022) & (USD/Unit)
Table 13. Global Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 14. Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 15. Global Cancer Immunotherapies Revenue by Application (2017-2022)
Table 16. Global Cancer Immunotherapies Revenue Market Share by Application (2017-2022)
Table 17. Global Cancer Immunotherapies Sale Price by Application (2017-2022) & (USD/Unit)
Table 18. Global Cancer Immunotherapies Sales by Company (2020-2022) & (K Units)
Table 19. Global Cancer Immunotherapies Sales Market Share by Company (2020-2022)
Table 20. Global Cancer Immunotherapies Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Cancer Immunotherapies Revenue Market Share by Company (2020-2022)
Table 22. Global Cancer Immunotherapies Sale Price by Company (2020-2022) & (USD/Unit)
Table 23. Key Manufacturers Cancer Immunotherapies Producing Area Distribution and Sales Area
Table 24. Players Cancer Immunotherapies Products Offered
Table 25. Cancer Immunotherapies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Cancer Immunotherapies Sales by Geographic Region (2017-2022) & (K Units)
Table 29. Global Cancer Immunotherapies Sales Market Share Geographic Region (2017-2022)
Table 30. Global Cancer Immunotherapies Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Cancer Immunotherapies Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Cancer Immunotherapies Sales by Country/Region (2017-2022) & (K Units)
Table 33. Global Cancer Immunotherapies Sales Market Share by Country/Region (2017-2022)
Table 34. Global Cancer Immunotherapies Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 37. Americas Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 38. Americas Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 40. Americas Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 41. Americas Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 42. Americas Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 43. Americas Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 44. APAC Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
Table 45. APAC Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Table 46. APAC Cancer Immunotherapies Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
Table 48. APAC Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 49. APAC Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 50. APAC Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 51. APAC Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 52. Europe Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 53. Europe Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 54. Europe Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 56. Europe Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 57. Europe Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 58. Europe Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 59. Europe Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 61. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 65. Middle East & Africa Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 67. Middle East & Africa Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Cancer Immunotherapies
Table 69. Key Market Challenges & Risks of Cancer Immunotherapies
Table 70. Key Industry Trends of Cancer Immunotherapies
Table 71. Cancer Immunotherapies Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Cancer Immunotherapies Distributors List
Table 74. Cancer Immunotherapies Customer List
Table 75. Global Cancer Immunotherapies Sales Forecast by Region (2023-2028) & (K Units)
Table 76. Global Cancer Immunotherapies Sales Market Forecast by Region
Table 77. Global Cancer Immunotherapies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Cancer Immunotherapies Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 80. Americas Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Cancer Immunotherapies Sales Forecast by Region (2023-2028) & (K Units)
Table 82. APAC Cancer Immunotherapies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Europe Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 86. Middle East & Africa Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Cancer Immunotherapies Sales Forecast by Type (2023-2028) & (K Units)
Table 88. Global Cancer Immunotherapies Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Cancer Immunotherapies Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Cancer Immunotherapies Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Cancer Immunotherapies Sales Forecast by Application (2023-2028) & (K Units)
Table 92. Global Cancer Immunotherapies Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Cancer Immunotherapies Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Cancer Immunotherapies Revenue Market Share Forecast by Application (2023-2028)
Table 95. Amgen Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 96. Amgen Cancer Immunotherapies Product Offered
Table 97. Amgen Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 98. Amgen Main Business
Table 99. Amgen Latest Developments
Table 100. AstraZeneca Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Cancer Immunotherapies Product Offered
Table 102. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Roche Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 106. Roche Cancer Immunotherapies Product Offered
Table 107. Roche Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 108. Roche Main Business
Table 109. Roche Latest Developments
Table 110. Bristol-Myers Squibb Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 111. Bristol-Myers Squibb Cancer Immunotherapies Product Offered
Table 112. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 113. Bristol-Myers Squibb Main Business
Table 114. Bristol-Myers Squibb Latest Developments
Table 115. Bayer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 116. Bayer Cancer Immunotherapies Product Offered
Table 117. Bayer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 118. Bayer Main Business
Table 119. Bayer Latest Developments
Table 120. Merck Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 121. Merck Cancer Immunotherapies Product Offered
Table 122. Merck Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 123. Merck Main Business
Table 124. Merck Latest Developments
Table 125. ARMO BioSciences (Eli Lilly) Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 126. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Offered
Table 127. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 128. ARMO BioSciences (Eli Lilly) Main Business
Table 129. ARMO BioSciences (Eli Lilly) Latest Developments
Table 130. Novartis Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 131. Novartis Cancer Immunotherapies Product Offered
Table 132. Novartis Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 133. Novartis Main Business
Table 134. Novartis Latest Developments
Table 135. Pfizer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 136. Pfizer Cancer Immunotherapies Product Offered
Table 137. Pfizer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 138. Pfizer Main Business
Table 139. Pfizer Latest Developments
Table 140. Johnson & Johnson Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 141. Johnson & Johnson Cancer Immunotherapies Product Offered
Table 142. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 143. Johnson & Johnson Main Business
Table 144. Johnson & Johnson Latest Developments
Table 145. AbbVie Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 146. AbbVie Cancer Immunotherapies Product Offered
Table 147. AbbVie Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 148. AbbVie Main Business
Table 149. AbbVie Latest Developments
Table 150. Gilead Sciences Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 151. Gilead Sciences Cancer Immunotherapies Product Offered
Table 152. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 153. Gilead Sciences Main Business
Table 154. Gilead Sciences Latest Developments
Table 1. Cancer Immunotherapies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Cancer Immunotherapies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies (MABs)
Table 4. Major Players of Cancer Vaccines
Table 5. Major Players of Immunomodulators
Table 6. Major Players of Adoptive Cell transfer
Table 7. Major Players of Checkpoint Inhibitors
Table 8. Global Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 9. Global Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 10. Global Cancer Immunotherapies Revenue by Type (2017-2022) & ($ million)
Table 11. Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
Table 12. Global Cancer Immunotherapies Sale Price by Type (2017-2022) & (USD/Unit)
Table 13. Global Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 14. Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 15. Global Cancer Immunotherapies Revenue by Application (2017-2022)
Table 16. Global Cancer Immunotherapies Revenue Market Share by Application (2017-2022)
Table 17. Global Cancer Immunotherapies Sale Price by Application (2017-2022) & (USD/Unit)
Table 18. Global Cancer Immunotherapies Sales by Company (2020-2022) & (K Units)
Table 19. Global Cancer Immunotherapies Sales Market Share by Company (2020-2022)
Table 20. Global Cancer Immunotherapies Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Cancer Immunotherapies Revenue Market Share by Company (2020-2022)
Table 22. Global Cancer Immunotherapies Sale Price by Company (2020-2022) & (USD/Unit)
Table 23. Key Manufacturers Cancer Immunotherapies Producing Area Distribution and Sales Area
Table 24. Players Cancer Immunotherapies Products Offered
Table 25. Cancer Immunotherapies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Cancer Immunotherapies Sales by Geographic Region (2017-2022) & (K Units)
Table 29. Global Cancer Immunotherapies Sales Market Share Geographic Region (2017-2022)
Table 30. Global Cancer Immunotherapies Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Cancer Immunotherapies Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Cancer Immunotherapies Sales by Country/Region (2017-2022) & (K Units)
Table 33. Global Cancer Immunotherapies Sales Market Share by Country/Region (2017-2022)
Table 34. Global Cancer Immunotherapies Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 37. Americas Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 38. Americas Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 40. Americas Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 41. Americas Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 42. Americas Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 43. Americas Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 44. APAC Cancer Immunotherapies Sales by Region (2017-2022) & (K Units)
Table 45. APAC Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Table 46. APAC Cancer Immunotherapies Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Cancer Immunotherapies Revenue Market Share by Region (2017-2022)
Table 48. APAC Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 49. APAC Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 50. APAC Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 51. APAC Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 52. Europe Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 53. Europe Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 54. Europe Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 56. Europe Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 57. Europe Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 58. Europe Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 59. Europe Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Cancer Immunotherapies Sales by Country (2017-2022) & (K Units)
Table 61. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Cancer Immunotherapies Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Cancer Immunotherapies Sales by Type (2017-2022) & (K Units)
Table 65. Middle East & Africa Cancer Immunotherapies Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Cancer Immunotherapies Sales by Application (2017-2022) & (K Units)
Table 67. Middle East & Africa Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Cancer Immunotherapies
Table 69. Key Market Challenges & Risks of Cancer Immunotherapies
Table 70. Key Industry Trends of Cancer Immunotherapies
Table 71. Cancer Immunotherapies Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Cancer Immunotherapies Distributors List
Table 74. Cancer Immunotherapies Customer List
Table 75. Global Cancer Immunotherapies Sales Forecast by Region (2023-2028) & (K Units)
Table 76. Global Cancer Immunotherapies Sales Market Forecast by Region
Table 77. Global Cancer Immunotherapies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Cancer Immunotherapies Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 80. Americas Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Cancer Immunotherapies Sales Forecast by Region (2023-2028) & (K Units)
Table 82. APAC Cancer Immunotherapies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Europe Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Cancer Immunotherapies Sales Forecast by Country (2023-2028) & (K Units)
Table 86. Middle East & Africa Cancer Immunotherapies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Cancer Immunotherapies Sales Forecast by Type (2023-2028) & (K Units)
Table 88. Global Cancer Immunotherapies Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Cancer Immunotherapies Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Cancer Immunotherapies Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Cancer Immunotherapies Sales Forecast by Application (2023-2028) & (K Units)
Table 92. Global Cancer Immunotherapies Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Cancer Immunotherapies Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Cancer Immunotherapies Revenue Market Share Forecast by Application (2023-2028)
Table 95. Amgen Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 96. Amgen Cancer Immunotherapies Product Offered
Table 97. Amgen Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 98. Amgen Main Business
Table 99. Amgen Latest Developments
Table 100. AstraZeneca Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Cancer Immunotherapies Product Offered
Table 102. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Roche Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 106. Roche Cancer Immunotherapies Product Offered
Table 107. Roche Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 108. Roche Main Business
Table 109. Roche Latest Developments
Table 110. Bristol-Myers Squibb Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 111. Bristol-Myers Squibb Cancer Immunotherapies Product Offered
Table 112. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 113. Bristol-Myers Squibb Main Business
Table 114. Bristol-Myers Squibb Latest Developments
Table 115. Bayer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 116. Bayer Cancer Immunotherapies Product Offered
Table 117. Bayer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 118. Bayer Main Business
Table 119. Bayer Latest Developments
Table 120. Merck Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 121. Merck Cancer Immunotherapies Product Offered
Table 122. Merck Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 123. Merck Main Business
Table 124. Merck Latest Developments
Table 125. ARMO BioSciences (Eli Lilly) Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 126. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Offered
Table 127. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 128. ARMO BioSciences (Eli Lilly) Main Business
Table 129. ARMO BioSciences (Eli Lilly) Latest Developments
Table 130. Novartis Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 131. Novartis Cancer Immunotherapies Product Offered
Table 132. Novartis Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 133. Novartis Main Business
Table 134. Novartis Latest Developments
Table 135. Pfizer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 136. Pfizer Cancer Immunotherapies Product Offered
Table 137. Pfizer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 138. Pfizer Main Business
Table 139. Pfizer Latest Developments
Table 140. Johnson & Johnson Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 141. Johnson & Johnson Cancer Immunotherapies Product Offered
Table 142. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 143. Johnson & Johnson Main Business
Table 144. Johnson & Johnson Latest Developments
Table 145. AbbVie Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 146. AbbVie Cancer Immunotherapies Product Offered
Table 147. AbbVie Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 148. AbbVie Main Business
Table 149. AbbVie Latest Developments
Table 150. Gilead Sciences Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 151. Gilead Sciences Cancer Immunotherapies Product Offered
Table 152. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 153. Gilead Sciences Main Business
Table 154. Gilead Sciences Latest Developments
LIST OF FIGURES
Figure 1. Picture of Cancer Immunotherapies
Figure 2. Cancer Immunotherapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Immunotherapies Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Cancer Immunotherapies Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Cancer Immunotherapies Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Monoclonal Antibodies (MABs)
Figure 10. Product Picture of Cancer Vaccines
Figure 11. Product Picture of Immunomodulators
Figure 12. Product Picture of Adoptive Cell transfer
Figure 13. Product Picture of Checkpoint Inhibitors
Figure 14. Global Cancer Immunotherapies Sales Market Share by Type in 2021
Figure 15. Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
Figure 16. Cancer Immunotherapies Consumed in Breast Cancer
Figure 17. Global Cancer Immunotherapies Market: Breast Cancer (2017-2022) & (K Units)
Figure 18. Cancer Immunotherapies Consumed in Leukemia
Figure 19. Global Cancer Immunotherapies Market: Leukemia (2017-2022) & (K Units)
Figure 20. Cancer Immunotherapies Consumed in Lymphoma
Figure 21. Global Cancer Immunotherapies Market: Lymphoma (2017-2022) & (K Units)
Figure 22. Cancer Immunotherapies Consumed in Melanoma
Figure 23. Global Cancer Immunotherapies Market: Melanoma (2017-2022) & (K Units)
Figure 24. Cancer Immunotherapies Consumed in Colorectal Cancer
Figure 25. Global Cancer Immunotherapies Market: Colorectal Cancer (2017-2022) & (K Units)
Figure 26. Cancer Immunotherapies Consumed in Non-Small Cell Lung Cancer
Figure 27. Global Cancer Immunotherapies Market: Non-Small Cell Lung Cancer (2017-2022) & (K Units)
Figure 28. Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Figure 29. Global Cancer Immunotherapies Revenue Market Share by Application in 2021
Figure 30. Cancer Immunotherapies Revenue Market by Company in 2021 ($ Million)
Figure 31. Global Cancer Immunotherapies Revenue Market Share by Company in 2021
Figure 32. Global Cancer Immunotherapies Sales Market Share by Geographic Region (2017-2022)
Figure 33. Global Cancer Immunotherapies Revenue Market Share by Geographic Region in 2021
Figure 34. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Figure 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region in 2021
Figure 36. Americas Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 37. Americas Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 38. APAC Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 39. APAC Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 40. Europe Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 41. Europe Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 42. Middle East & Africa Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 43. Middle East & Africa Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 44. Americas Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 45. Americas Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 46. United States Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 47. Canada Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 48. Mexico Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 49. Brazil Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 50. APAC Cancer Immunotherapies Sales Market Share by Region in 2021
Figure 51. APAC Cancer Immunotherapies Revenue Market Share by Regions in 2021
Figure 52. China Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 53. Japan Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 54. South Korea Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 55. Southeast Asia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 56. India Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 57. Australia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 58. Europe Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 59. Europe Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 60. Germany Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 61. France Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 62. UK Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 63. Italy Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 64. Russia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 65. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 66. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 67. Egypt Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 68. South Africa Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 69. Israel Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 70. Turkey Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 71. GCC Country Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Cancer Immunotherapies in 2021
Figure 73. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 74. Industry Chain Structure of Cancer Immunotherapies
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
Figure 1. Picture of Cancer Immunotherapies
Figure 2. Cancer Immunotherapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Immunotherapies Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Cancer Immunotherapies Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Cancer Immunotherapies Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Monoclonal Antibodies (MABs)
Figure 10. Product Picture of Cancer Vaccines
Figure 11. Product Picture of Immunomodulators
Figure 12. Product Picture of Adoptive Cell transfer
Figure 13. Product Picture of Checkpoint Inhibitors
Figure 14. Global Cancer Immunotherapies Sales Market Share by Type in 2021
Figure 15. Global Cancer Immunotherapies Revenue Market Share by Type (2017-2022)
Figure 16. Cancer Immunotherapies Consumed in Breast Cancer
Figure 17. Global Cancer Immunotherapies Market: Breast Cancer (2017-2022) & (K Units)
Figure 18. Cancer Immunotherapies Consumed in Leukemia
Figure 19. Global Cancer Immunotherapies Market: Leukemia (2017-2022) & (K Units)
Figure 20. Cancer Immunotherapies Consumed in Lymphoma
Figure 21. Global Cancer Immunotherapies Market: Lymphoma (2017-2022) & (K Units)
Figure 22. Cancer Immunotherapies Consumed in Melanoma
Figure 23. Global Cancer Immunotherapies Market: Melanoma (2017-2022) & (K Units)
Figure 24. Cancer Immunotherapies Consumed in Colorectal Cancer
Figure 25. Global Cancer Immunotherapies Market: Colorectal Cancer (2017-2022) & (K Units)
Figure 26. Cancer Immunotherapies Consumed in Non-Small Cell Lung Cancer
Figure 27. Global Cancer Immunotherapies Market: Non-Small Cell Lung Cancer (2017-2022) & (K Units)
Figure 28. Global Cancer Immunotherapies Sales Market Share by Application (2017-2022)
Figure 29. Global Cancer Immunotherapies Revenue Market Share by Application in 2021
Figure 30. Cancer Immunotherapies Revenue Market by Company in 2021 ($ Million)
Figure 31. Global Cancer Immunotherapies Revenue Market Share by Company in 2021
Figure 32. Global Cancer Immunotherapies Sales Market Share by Geographic Region (2017-2022)
Figure 33. Global Cancer Immunotherapies Revenue Market Share by Geographic Region in 2021
Figure 34. Global Cancer Immunotherapies Sales Market Share by Region (2017-2022)
Figure 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region in 2021
Figure 36. Americas Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 37. Americas Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 38. APAC Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 39. APAC Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 40. Europe Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 41. Europe Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 42. Middle East & Africa Cancer Immunotherapies Sales 2017-2022 (K Units)
Figure 43. Middle East & Africa Cancer Immunotherapies Revenue 2017-2022 ($ Millions)
Figure 44. Americas Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 45. Americas Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 46. United States Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 47. Canada Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 48. Mexico Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 49. Brazil Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 50. APAC Cancer Immunotherapies Sales Market Share by Region in 2021
Figure 51. APAC Cancer Immunotherapies Revenue Market Share by Regions in 2021
Figure 52. China Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 53. Japan Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 54. South Korea Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 55. Southeast Asia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 56. India Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 57. Australia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 58. Europe Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 59. Europe Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 60. Germany Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 61. France Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 62. UK Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 63. Italy Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 64. Russia Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 65. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country in 2021
Figure 66. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country in 2021
Figure 67. Egypt Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 68. South Africa Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 69. Israel Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 70. Turkey Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 71. GCC Country Cancer Immunotherapies Revenue Growth 2017-2022 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Cancer Immunotherapies in 2021
Figure 73. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 74. Industry Chain Structure of Cancer Immunotherapies
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
